Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
Novartis
Hoosier Cancer Research Network
Charles Drew University of Medicine and Science
Institute of Cancer Research, United Kingdom
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
St. Jude Children's Research Hospital
University of California, San Francisco
Janssen Research & Development, LLC
Blue Earth Therapeutics Ltd
Celcuity Inc
7 Hills Pharma, LLC
University of Michigan Rogel Cancer Center
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of Arizona
Beijing Biotech
Parabilis Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Minghui Pharmaceutical (Hangzhou) Ltd
National Institutes of Health Clinical Center (CC)
AstraZeneca
National Institutes of Health Clinical Center (CC)
West China Hospital
Pathos AI, Inc.
Pfizer
Pfizer
National Institutes of Health Clinical Center (CC)
NRG Oncology
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
H. Lee Moffitt Cancer Center and Research Institute
State University of New York at Buffalo
Radiopharm Theranostics, Ltd
Astellas Pharma Inc
Fudan University
ImmunityBio, Inc.
Aulos Bioscience, Inc.
Arsenal Biosciences, Inc.
Bristol-Myers Squibb
Janssen Research & Development, LLC
Medical University of South Carolina
Mayo Clinic